Domain Therapeutics Strengthens Leadership Team to Spearhead Global Development and North American Expansion as the Leading GPCR Immuno-Oncology Company
- None.
- None.
- Michael Gottlieb appointed as Chairman of the Board of Directors
- Dr. Anthony Johnson appointed as President and Chief Executive Officer
Anthony Johnson (Photo: Domain Therapeutics)
Michael’s appointment as Chairman follows Laurence Rulleau and Youssef Bennani, who held the role for 9 years. An industry expert with international experience leading biopharmaceutical companies, Michael is also currently the President and Chief Executive Officer of RENOGENYX. Michael was the founding Chief Commercial Officer of POINT Biopharma (PNT:NASDAQ), where he was responsible for global commercial operations and market strategy and previously held leadership roles with Sanofi Genzyme.
As the new President and CEO, based in
Mr. Michael Gottlieb, Chairman of the Board of Directors at Domain Therapeutics, said: “I am excited to work with our board and team to make Domain a recognized leader in its field and in the US to unlock new possibilities in GPCR targeted cancer immunotherapies.”
Dr. Tony Johnson, newly appointed President and Chief Executive Officer of Domain Therapeutics, said: “I am honored to have the opportunity to lead at this pivotal time in the Company’s development and to work alongside the incredible team to accelerate our innovative and uniquely positioned GPCR-derived immuno-oncology programs and expand our US market presence.”
Laurence Rulleau, Director of Domain Therapeutics, commented: “With my co-lead partners, I would like to welcome Michael and Tony to our leadership team. Their respective expertise and track record in pioneering and leading biopharmaceutical companies will be invaluable to the Company and will support our reach and global focus. I would like to thank Pascal for his steadfast commitment, loyalty and service to the Company and the Board over the last fifteen years, enabling the significant growth of the Company.”
Pascal
– ENDS
About Domain Therapeutics
https://www.domaintherapeutics.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20240108886645/en/
For more information, please contact:
ICR Consilium
Amber Fennell, Namrata Taak
Email: DomainTherapeutics@consilium-comms.com
Tel: +44 (0)20 3709 5813
Source: Domain Therapeutics
FAQ
Who was appointed as Chairman of the Board of Directors of Domain Therapeutics?
Who was appointed as President and Chief Executive Officer of Domain Therapeutics?
What is the focus of Domain Therapeutics' drug candidates?
What is the background of Michael Gottlieb, the newly appointed Chairman of Domain Therapeutics?